Mefenamic Acid for COVID-19: real-time analysis

Download Image

Post

c19early.org

Mefenamic Acid for COVID-19

1 study with 36 patients

Serious outcome risk

Mefenamic Acid

Control

No significant improvements are seen in meta-analysis to date.

COVID-19 Mefenamic Acid studies · October 2026

Outcome (studies)

Improvement

Relative risk · 95% CI

All studies (1)−189%

Hospitalization (1)−189%

RCTs (1)−189%

Early (1)−189%

00.511.5+

← Mefenamic Acid
reduces riskIncreased
risk →

.hmva--anim-stagger .hmva__row{opacity:1}.hmva--anim .hmva__shade{opacity:var(--shade-opacity)}.hmva--anim-stagger .est .ci{transform:translateY(-50%)}.hmva--anim-stagger .est .pt{transform:translate(-50%,-50%)}.hmva--anim-stagger .hmva__bar{transform:none}.hmva--anim-settle .est .pt{left:calc(min(var(--pt), 1.5) / var(--max) * 100%)}.hmva--anim-settle .est .ci{left:calc(var(--lo) / var(--max) * 100%);width:calc((var(--hi) - var(--lo)) / var(--max) * 100%)}.hmva--anim-settle .hmva__bar--drug{width:calc(min(1, var(--rr)) * 100%)}.hmva--anim-settle .hmva__bar--control{width:calc(min(1, 1 / var(--rr)) * 100%)}


Jan 14 2022	Guzman‑Esquivel et al., International Journal of Molecular Medicine, doi:10.3892/ijmm.2022.5084	Efficacy of the use of mefenamic acid combined with standard medical care vs. standard medical care alone for the treatment of COVID‑19: A randomized double‑blind placebo‑controlled trial
Jan 14 2022	94% improved recovery (p=0.03). RCT 36 COVID-19 outpatients showing reduced time to an "acceptable symptom state" with mefenamic acid treatment, however the effect was driven by pain-related symptoms and is likely, at least in part, due to mefenamic acid’s ana..